Search Results for "ordered"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ordered. Results 11 to 20 of 153 total matches.

Twinrix: A Combination Hepatitis A and B Vaccine

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 2001  (Issue 1110)
A. In decreasing order of prevalence, they are: Arizona, Alaska, Oregon, New Mexico, Utah, Washington, Oklahoma ...
A vaccine to prevent both Hepatitis A and Hepatitis B (Twinrix), previously licensed in Canada and Europe, is now available in the US for adults.
Med Lett Drugs Ther. 2001 Aug 6;43(1110):67-8 |  Show IntroductionHide Introduction

Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
significantly improves sexual desire in women. Behav Res Ther 2014; 57:43. 5. FDA. FDA orders important safety ...
The FDA has approved bremelanotide (Vyleesi – Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin (Addyi), which was approved in 2015, was the first.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-6 |  Show IntroductionHide Introduction

Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • May 12, 2025  (Issue 1728)
dose pens and prefilled syringes and one 200-mg injection given consecutively in any order) at week 12 ...
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya), are also approved for treatment of CD.
Med Lett Drugs Ther. 2025 May 12;67(1728):78-80   doi:10.58347/tml.2025.1728d |  Show IntroductionHide Introduction

In Brief: Pancreatic Enzyme Replacement Products

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017  (Issue 1531)
that they would have to submit a new drug application by April 2010 in order to keep their products on the market ...
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal FDA approval was required; in 1991, however, the FDA told all manufacturers of pancreatic enzyme replacement products that they would have to submit a new drug application by April 2010 in order to keep their products on the market.EPI is a chronic disorder characterized by a deficiency of exocrine pancreatic enzymes, which results in malabsorption, steatorrhea, and weight loss. Irreversible EPI is...
Med Lett Drugs Ther. 2017 Oct 9;59(1531):170 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
: states and territories can continue to order both products. December 31, 2021. Available at: https ...
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16 |  Show IntroductionHide Introduction

The Atkins Diet

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
; special fees for bulk orders). Major credit cards accepted. Subscriptions are accepted ...
Nearly 30 years after the first publication of Dr. Atkins' Diet Revolution promoting a high-protein, extremely low-carbohydrate diet, patients once again are asking their physicians about the Atkins diet.
Med Lett Drugs Ther. 2000 Jun 12;42(1080):52 |  Show IntroductionHide Introduction

Docosanol Cream (Abreva) for Recurrent Herpes Labialis

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000  (Issue 1092)
subscriptions to students, interns, residents, and fellows in the USA and Canada; special fees for bulk orders ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
Med Lett Drugs Ther. 2000 Nov 13;42(1092):108 |  Show IntroductionHide Introduction

Once-a-week Alendronate (Fosamax)

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
and Canada; special fees for bulk orders). Major credit cards accepted. Subscriptions are accepted ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):26 |  Show IntroductionHide Introduction

In Brief: Plan B OTC

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
to $40. In order to enforce the age restriction, the drug will be kept behind the pharmacist’s counter ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Med Lett Drugs Ther. 2006 Sep 11;48(1243):75 |  Show IntroductionHide Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
(the components of Adacel are listed in a different order and are labeled as “reduced” diphtheria toxoid ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 |  Show IntroductionHide Introduction